What Is Fair Pricing For Medicines? WHO-Netherlands Forum Aims To Find Out 01/03/2017 by William New, Intellectual Property Watch 4 Comments Public health stakeholders – and just about everyone else – may take notice of a meeting planned for May in the Netherlands, as it could offer the beginning of a new approach to pharmaceutical costs. High drug prices have become a ‘kitchen table’ issue in countries of all economic sizes recently, and the World Health Organization is teaming up with the Dutch government to address it in a new and practical way.
Global Fund Hits Reset On Executive Director Search 28/02/2017 by William New, Intellectual Property Watch 4 Comments The Global Fund to Fight AIDS, Tuberculosis and Malaria is deliberating on how to start over on its search for a new executive director after questions arose near the end of the process.
US Business, Government Work To Bring Down ‘Dangerous’ UN Panel Report On Access To Medicines – And Change The Debate In Geneva 23/02/2017 by William New, Intellectual Property Watch 3 Comments Calling it flawed and narrow and seemingly threatened by its contents, the leading United States business group and US government IP specialists are working to limit the impact of a recent United Nations report that made recommendations for the decades-old problem of ensuring affordable medicines reach people when they are under patent in a way that does not threaten innovation. One step in countering the UN report? Change the discourse in Geneva and elsewhere.
Special Report: WHO Board Sets Review Of 10-Year Effort To Boost Medicines Access, Affordability 16/02/2017 by William New, Intellectual Property Watch 1 Comment Once considered a breakthrough in negotiations to address problems of making cutting-edge medical products and research available to poor countries, the decade-old World Health Organization Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA) is now undergoing review, with the WHO Executive Board calling for a report on the initiative and plans for its future next year.
Leadership Rotation For Fight The Fakes Campaign 09/02/2017 by Intellectual Property Watch 1 Comment A new industry group today took the reins of the Fight the Fakes campaign, a growing coalition against fake medicines, the first rotation in leadership since its launch in late 2013.
US Chamber International IP Index: US, Europe At Top; India Needs A Push 08/02/2017 by William New, Intellectual Property Watch 2 Comments The United States Chamber of Commerce today released its fifth annual International IP Index, which makes the case for the positive impact of intellectual property on economies. The United States scored highest, followed by top European economies and Japan. And near the bottom was India, despite recent efforts to accept the IP system. Separately, the report assesses international trade rules for IP and argues for nations to negotiate “TRIPS-plus” agreements.
WTO Members Celebrate Treaty Amendment On Medicines Access, Look Ahead 30/01/2017 by William New, Intellectual Property Watch 3 Comments A high-level meeting at the World Trade Organization today welcomed in an amendment to international trade rules for intellectual property aimed at boosting exports of affordable medicines. It also set out the way ahead to make it work.
WHO Board Agrees To Drop The Word ‘Counterfeit’ After 30 Years 30/01/2017 by William New, Intellectual Property Watch 2 Comments For nearly 30 years, the United Nations World Health Organization has been referring to poor-quality and fake medicines as counterfeit. But that is about to change.
WHO, Netherlands To Hold Fair Drug Pricing Forum In May 27/01/2017 by Intellectual Property Watch 2 Comments The World Health Organization and The Netherlands government will co-host a meeting in the spring that brings experts together to look at high drug prices and the purchasing of medicines.
US Army Extends Comment Period On Proposed Exclusive Zika Licence 27/01/2017 by Intellectual Property Watch 3 Comments The US Army has extended the comment period on the proposed licence to pharmaceutical company Sanofi on technology necessary to create a vaccine for the Zika virus. This is the second extension, and will permit public comments through 10 March 2017.